1532 / 2894
94. Centers for Disease Control Prevention: Adverse
ocular reactions following transfusion—United
States 1997-1998. JAMA 279:49, 1998.
95. Vamvakas EC: Transfusion-related immunomodu-
lation. Transfusion Alternatives in Transfusion Med
4:48, 2002.
96. Corwin HL, AuBuchon JP: Is leukoreduction of
blood components for everyone? JAMA 289:1993,
2003.
97. Vamvakas EC, Blajchman MA: Universal WBC
reduction: A case for and against. Transfusion
41:691, 2001.
98. Hebert PC, Fergusson DA, Blajchman MA, et al:
Clinical outcomes following institution of the
Canadian Universal leukoreduction program for
red blood cell transfusions. JAMA 289:1941, 2003.
99. Cull DL, Lally KP, Murphy KD: Compatibility of
packed erythrocytes and Ringer’s lactate solution.
Surg Gynecol Obstet 173:12, 1991.
100. Morrow JF, Braine HG, Kickler TS, et al: Septic
reactions to platelet transfusions. JAMA 266:255,
1991.
101. Goodnough LT, Brecher ME, Kanter MH, et al:
Transfusion medicine. I. Blood transfusion. N Engl
J Med 340:438, 1999.
102. Kruskall MS: The perils of platelet transfusions. N
Engl J Med 337:1914, 1997.
103. Dunne WM, Case LK, Isgriggs L: In-house valida-
tion of the BACTEC 9240 blood culture system for
detection of bacterial contamination in platelet
concentrates. Transfusion 45:1138-1142, 2005.
104. Eder AF, Kennedy JM, Dy B, et al: Bacterial scree-
ning of apheresis platelets and the residual risk of
septic transfusion reactions: the American Red
Cross experience (2004-2006). Transfusion 47:
1134-1142, 2007.
105. Cardigan R, Lawrie AS, Mackie IJ: The quality of
fresh-frozen plasma produced from whole blood
stored at 4°C overnight. Transfusion 45:1342-1348,
2005.
106. Brown B, Steed DL, Webster MW, et al: General
surgery in adult hemophiliacs. Surgery 99:154, 1986.
107. White GC, McMillan CW, Kindon HS, et al: Use of
recombinant antihemophiliac factor in the treat-
ment of two patients with classic hemophilia. N
Engl J Med 320:164, 1989.
108. Goodnough LT, Brecher ME, Kanter MH: Transfu-
sion medicine. II. Blood conservation. N Engl J Med
340:525, 1999.
109. Centers for Disease Control: Bacterial sepsis asso-
ciated with the receipt of albumin. JAMA 276:1373,
1996.
110. Vincent JL, Wilkes MM, Navickis RJ: Safety of
human albumin—serious adverse events reported
world wide in 1998-2002. Br J Anaesth 91:625,
2003.
111. Vermeulen LC, Ratko TA, Erstad BL, et al: The
university hospital consortium guidelines for the
use of albumin, nonprotein colloid and crystalloid
solutions. Arch Intern Med 155:373, 1995.
112. Boldt J: New light on intravascular volume replace-
ment regimens: What did we learn from the past
three years? Anesth Analg 97:1595, 2003.
113. Friedman Z, Berkenstadt H, Preisman S, et al: A
comparison of lactated Ringer’s solution to hydroxy
ethyl starch 6% in a model of severe hemorrhagic
shock and continuous bleeding in dogs. Anesth
Analg 96:39, 2003.
114. Wilkes NJ, Woolf RL, PowandaMC, et al: Hydroxye-
thyl starch in balanced electrolyte solution
(Hextend)—Pharmacokinetic and pharmacodyna-
mics profiles in healthy volunteers. Anesth Analg
94:538, 2002.
115. Asfar P, Kerkeni N, Labadie F, et al: Assessment of
hemodynamic and gastric mucosal acidosis with
modified fluid gelatin versus hydroxyethyl starch.
Intensive Care Med 26:1282, 2000.
116. Ljungström KG, Renck H, Hedin H, et al: Hapten
inhibition and dextran anaphylaxis. Anaesthesia
43:729, 1988.
117. Drobin D, Hahn RG: Kinetics of isotonic and
hypertonic plasma volume expanders. AnesthAnalg
96:1371, 2002.
118. Tremper KK, Friedman AE, Levine EM, et al: The
preoperative treatment of severely anemic patients
with perfluorochemical oxygen transport fluid,
Fluosol-DA. N Engl J Med 307:277, 1982.
119. Looker D, Abbott-Brown D, Cozart P: A human
recombinant haemoglobin designed for use as a
blood substitute. Nature 356:258, 1992.
120. Hermann J, Corso C, Messmer KF: Resuscitation
with recombitant hemoglobin rHb 2.0 in a rodent
model of hemorrhagic shock. Anesthesiology
107:273-280, 2007.
121. Crawford MW, Shichor T, Engelhardt T: The novel
hemoglobin-based oxygen carrier HRC 101 impro-
ves survival in murine sickle cell disease. Anesthe-
siology 107:281-287, 2007.
122. Levy J: The use of haemoglobin glutamer-250
(HBOC-201) as an oxygen bridge in patients with
acute anaemia associated with surgical blood loss.
Expert Opin Biol Ther 3:509, 2003.
123. Wahr JA: The use of bovine hemoglobin gluta-
mer-250 (Hemopure) in surgical patients: Results of
a multicenter, randomized, single-blinded trial.
Anesth Analg 94:799, 2002.
124. Natanson C, Kern SJ, Lurie P, et al: Cell-free hemo-
globin-based blood substitutes and risk of myocar-
dial infarction and death. JAMA 299:2305-2312,
2008.
125. Fergusson DA, McIntyre L: The future of clinical
trials evaluating blood substitutes. JAMA 299:2324-
2326, 2008.
126. Engel HL: Medicolegal considerations in blood
transfusion. In Petz LD, Swisher SN (eds): Clinical
Practice of Blood Transfusion, 2nd ed. New York,
Churchill Livingstone, 1989, p 355.
1532
Control de la anestesia
III